3-<1-(2,6-dimethyl)piperidinyl>propanamine | 68497-66-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-<1-(2,6-dimethyl)piperidinyl>propanamine
• 英文别名: 3-(cis-2,6-dimethylpiperidin-1-yl)propan-1-amine；3-(2,6-dimethyl-1-piperidinyl)propyl amine；3-(2r,6c-dimethyl-piperidino)-propylamine；3-(2r,6c-Dimethyl-piperidino)-propylamin；3-((2R,6S)-2,6-dimethylpiperidin-1-yl)propan-1-amine；3-[(cis)-2,6-dimethyl-1-piperidinyl]propylamine；cis-3-[2,6-Dimethylpiperidinyl]propylamine；3-[(2S,6R)-2,6-dimethylpiperidin-1-yl]propan-1-amine
• CAS: 68497-66-5；869493-57-2
• 化学式: C₁₀H₂₂N₂
• 分子量: 170.298
• InChiKey: GHJFLCNNVJBMEX-AOOOYVTPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-<1-(2,6-dimethyl)piperidinyl>propanamine 在 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 11.0h， 生成
  参考文献：
  名称：

  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

  摘要：

  The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-4,4-difluorocyclohexyl)piperidin-4-yl] -6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00680
• 作为产物：
  描述：

  3-<1-(2,6-dimethyl)piperidinyl>propanenitrile 在 lithium aluminium tetrahydride 、 三氯化铝 作用下， 以 乙醚 、 甲苯 为溶剂， 反应 6.0h， 生成 3-<1-(2,6-dimethyl)piperidinyl>propanamine
  参考文献：
  名称：

  一系列N-[（二取代-氨基）烷基] -2-氧代-1-吡咯烷乙酰胺（包括普拉美沙坦）的失忆活动。

  摘要：

  合成了一系列的N-[（（二烷基氨基）烷基] -2-氧-1-吡咯烷乙酰胺。在ECS治疗后给药时，标题化合物可逆转小鼠电惊厥（ECS）引起的健忘症，并且在中枢神经系统（CNS）活性的一般观察性测试中无效。活性化合物表现出倒U形剂量反应曲线。在具有最宽剂量反应曲线和最有效化合物的化合物中，有以N- [2- [双（1-（甲基乙基）氨基]乙基]乙基或2,6-二甲基哌啶基乙基为酰胺取代基的化合物。N-（二烷基氨基）取代基可显着增强健忘症的逆转活性，乙烯可提供最佳链长。选择N- [2- [双（1-甲基乙基）氨基]乙基] -2-氧-1-吡啶基乙酰胺N-（二烷基氨基）取代基进行临床前毒理学评估，指定研究编号CI-879和美国采用的名称（ USAN）pramiracetam。普拉西坦在动物中显示出广泛的安全性，并且在正常人类志愿者中耐受性良好。在一项开放性试验中，它对患有原发性变性痴呆（PDD或老年痴呆型老年痴呆）的患者显示出令人鼓舞的活性。

  DOI：

  10.1021/jm00371a023

文献信息

• Super high specific activity tritium labelled receptor ligands - I. The use of polybromodiphenylacetic acid as a tritiation substrate. Synthesis of a tritium labelled sodium-channel blocker and angiotensin II antagonist with super high specific activity
  作者：Leyi Gong、Howard Parnes

  DOI：10.1002/(sici)1099-1344(199601)38:1<31::aid-jlcr806>3.0.co;2-c

  日期：1996.1

  PD-85639 (1) and the angiotensin II inhibitor EXP-655 (2) respectively. Preparation of (8) and (11) followed by reductive debromonation with carrier free tritium gas furnished the corresponding receptor ligands (1) and (2) having specific activities of 180 Ci/mmole and 209 Ci/mmole, respectively

  我们在此描述了多溴二苯乙酸 (4) 的合成，该片段分别为钠通道阻滞剂、PD-85639 (1) 和血管紧张素 II 抑制剂 EXP-655 (2) 的氚化底物 (8) 和 (11) 共有的片段. (8) 和 (11) 的制备，然后用无载体氚气还原脱溴，提供了相应的受体配体 (1) 和 (2)，其比活分别为 180 Ci/mmole 和 209 Ci/mmole
• Thienopyridinone compounds and methods of treatment
  申请人：Dhanoa S. Dale

  公开号：US20050256153A1

  公开（公告）日：2005-11-17

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  该发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻吩吡啶酮化合物，以及其合成和用于治疗由5-HT受体直接或间接介导的疾病。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、促动力、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、心房颤动、缺血性中风、胃炎、胃排空障碍、进食障碍、消化道疾病、便秘、勃起功能障碍和呼吸抑制。还包括其制备方法、新颖中间体和药用盐。
• N-(Substituted-aminoalkyl)-2-oxo-1-pyrrolidineacetamides
  申请人：Parke, Davis & Company

  公开号：US04145347A1

  公开（公告）日：1979-03-20

  N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidineacetamides which are useful as pharmacological agents, especially cognition activators, are disclosed. They can be produced by reacting a 2-oxo-1-pyrrolidineacetate ester with an appropriate amine.

  本文披露了一种作为药理学制剂，特别是认知激活剂有用的N-（取代氨基烷基）-2-氧代-1-吡咯烷乙酰胺。它们可以通过将2-氧代-1-吡咯烷乙酸酯与适当的胺反应而制备。
• Synthesis of thienopyridinone compounds and related intermediates
  申请人：Dhanoa S. Dale

  公开号：US20060084805A1

  公开（公告）日：2006-04-20

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  本发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻唑吡啶酮化合物及其合成和用途，用于治疗直接或间接通过5-HT受体介导的疾病。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、胃肠动力障碍、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、房颤、缺血性中风、胃炎、胃排空障碍、进食障碍、胃肠道疾病、便秘、勃起功能障碍和呼吸抑制。还包括制备方法、新型中间体和药物盐。
• FKBP inhibitors
  申请人：Pfizer Inc.

  公开号：US20040058905A1

  公开（公告）日：2004-03-25

  Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors. 1

  公式（I）的化合物，其盐和溶剂化物，在其中取代基如此描述，是FKBP抑制剂。